Skip to main navigation
Skip to search
Skip to main content
Providence Home
Search content at Providence
Home
Profiles
Research and Focus Areas
Grants and Projects
Research
Awards
Infliximab (Remicade) in the treatment of psoriatic arthritis
Philip Mease
Orthopedics
Washington
Research output
:
Contribution to journal
›
Review article
›
peer-review
13
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Infliximab (Remicade) in the treatment of psoriatic arthritis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Pharmacology, Toxicology and Pharmaceutical Science
Psoriatic Arthritis
100%
Infliximab
100%
Biological Product
50%
Tumor Necrosis Factor
50%
Tumor Necrosis Factor Inhibitor
33%
Psoriasis
33%
Placebo
16%
Inflammatory Disease
16%
Cytokine
16%
Rheumatoid Arthritis
16%
Skin Manifestation
16%
Immunopathology
16%
Inflammatory Arthritis
16%
Diseases
16%
Immunology and Microbiology
Infliximab
100%
Psoriatic Arthritis
100%
Biological Product
50%
Tumor Necrosis Factor Alpha
50%
TNF Inhibitor
33%
Inflammatory Arthritis
16%
Inflammatory Disorder
16%
Immunopathology
16%
Cytokine
16%